- Home
- CREV vs CNSP Comparison
CREV vs CNSP Comparison
Compare CREV & CNSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CREV | CNSP |
|---|---|---|
| Founded | 2007 | 2017 |
| Country | Australia | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4M | 3.8M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | CREV | CNSP |
|---|---|---|
| Price | $1.68 | $7.48 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $20.00 |
| AVG Volume (30 Days) | ★ 143.0K | 69.7K |
| Earning Date | 01-30-2026 | 11-17-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $47,677,475.00 | N/A |
| Revenue This Year | $40.32 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 86.77 | N/A |
| 52 Week Low | $1.48 | $4.93 |
| 52 Week High | $9.20 | $114.00 |
Technical Indicators
Market Signals| Indicator | CREV | CNSP |
|---|---|---|
| Relative Strength Index (RSI) | 42.97 | 58.78 |
| Support Level | $1.68 | $5.75 |
| Resistance Level | $1.82 | $8.92 |
| Average True Range (ATR) | 0.15 | 0.69 |
| MACD | 0.02 | 0.20 |
| Stochastic Oscillator | 3.87 | 47.75 |
Price Performance
Historical ComparisonAbout CREV Carbon Revolution Public Limited
Carbon Revolution PLC is an Australian-based technology company manufacturing carbon fiber wheels. It is an OEM supplier and a world-wide manufacturer of lightweight technology carbon fibre wheels to the automotive industry. The Company supplies wheels to OEMs across the globe for luxury and high-performance vehicles and SUVs, and is developing wheels for electric vehicles under contract for its OEM customers. The company generates maximum revenue Internationally.
About CNSP CNS Pharmaceuticals Inc.
CNS Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. It is involved in the development of Berubicin, which is a therapy for the treatment of glioblastoma. Glioblastomas are tumors that arise from astrocytes, which are star-shaped cells that make up the supportive tissue of the brain.